KLK3 and prostate cancer: The TITAN analysis further confirmed that the most significant benefits in rPFS—time to castration-resistant prostate cancer and PSA progression—were observed in patients who reached this nadir at 3 months, compared to those with PSA > 0.2 ng/mL [19].